White kidney bean extract,
does it really help with Inhibition of carbohydrate absorption and weight loss?
research showsA 12-participant acute trial found lower postprandial glucose and insulin excursions, and some RCTs reported weight and fat loss. However, an independent 2011 meta-analysis found no significant weight effect, while positive pooled and recent trials are concentrated in the proprietary Phase 2® product with manufacturer funding or consulting. The overall grade is C.
ads claimAdvertising calls it a 'carb blocker,' says it 'neutralizes carbohydrates,' or 'blocks calories from carbs.' Human research assessed postprandial values and short-term weight change with specific standardized products, not complete absorption blockade.
Useful facts when choosing a product
- Research products are generally standardized by alpha-amylase inhibitory activity in AAIU.
- Weight-trial doses range from 445 mg/day to 3 g/day or more.
- Many positive weight trials also used hypocaloric or high-carbohydrate dietary conditions.
- Bloating, gas, loose stool, bean allergy, and co-use with glucose-lowering medicines require safety distinction.
Chamgap Semantic Classification Code
Candidate index · review held
S.white-kidney-bean-extract.UNK.inhibition-of-carbohydrate-absorption-and-weight-loss.assess.placeboSupplements and nutraceuticals > White kidney bean extract > Unknown > Inhibition of carbohydrate absorption and weight loss > Association or change assessment > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Spadafranca 2013 used a 12-person crossover RCT and found that 100 mg of standardized extract reduced 3-hour postprandial glucose, insulin, and C-peptide excursions after a mixed meal. This did not directly quantify total carbohydrate absorption and used surrogate markers. Onakpoya 2011 found a negative pooled weight result and serious methodological limitations. Udani 2018 and Jäger 2024 reported small weight and fat loss with proprietary Phase 2®, but both had clear manufacturer links.
Why this is classified as C (45)
The absorption claim relies on small postprandial surrogate-marker studies, invoking boundary rule ①. Weight evidence conflicts between an independent negative meta-analysis and proprietary manufacturer-linked positive evidence, invoking rule ②-b. The overall grade is C with 45 points.
Counterpoint. A specific activity-standardized preparation may have small effects on postprandial glucose-insulin excursions and short-term weight.
Rejudgment record. New judgment — Absorption is supported by postprandial surrogates only; weight evidence conflicts between an independent negative meta-analysis and proprietary manufacturer-linked positive evidence, so boundary rules ① and ②-b cap the grade at C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Inhibition of carbohydrate absorption | C | A 12-person acute postprandial glucose-insulin surrogate study, not a direct total-absorption endpoint |
| Weight loss | C | Independent negative meta-analysis conflicts with proprietary manufacturer-linked positive evidence |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Spadafranca et al. 2013 | Randomized, double-blind, placebo-controlled acute crossover RCT | 12 participants | Indexed as non-U.S. government support | Postprandial glucose, insulin, C-peptide, and satiety | Reduced 3-hour excursions with 100 mg; small surrogate-marker study. | Mechanistic supportive |
| Onakpoya et al. 2011 | Independent systematic review and meta-analysis | 11 eligible; 6 pooled | Independent academic research | Body weight and body fat | Weight -1.77 kg, 95% CI -3.33 to 0.33, negative; serious methodological flaws in all RCTs. | Key limitation |
| Udani et al. 2018 | Proprietary-product systematic review and meta-analysis | 11 trials, 573 participants for weight | Pharmachem funded; author had consulting history | Body weight and body fat | Phase 2® weight -1.08 kg; manufacturer-supplied unpublished data included. | Positive with bias concern |
| Jäger et al. 2024 | 12-week randomized, double-blind, placebo-controlled RCT | 90 randomized; 81 completed | Sponsored by InQpharm; supported by Perrigo, Pharmachem, and Fytexia; author consulting | Weight, BMI, fat mass, and circumferences | 2.1 and 3 g/day plus a hypocaloric diet reduced outcomes versus placebo. | Positive with industry links |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] White kidney bean extract (Phaseolus vulgaris) x inhibition of carbohydrate absorption and weight loss — Evidence Grade C·45. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/white-kidney-bean-carb-absorption-weight/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.